[Recent progress in application of local drug delivery for preventing restenosis after peripheral arterial revascularization].
Restenosis following vascular revascularization remains an important clinical problem. Local drug delivery which can provide enough drug concentration in the lesion location without causing adverse systemic effect is an excellent solution for this question. We conducted a systematic literatory search on PubMed and CKNI through May 2014. After reviewing all related papers, we provided a comprehensive overview of the available drugs and techniques for local drug delivery that have been developed to prevent restenosis after peripheral vascular interventions, including innovations that have been tested only in animals as well as those already approved for clinical use. In brief, anti-proliferative drugs such as paclitaxel and sirolimus are the most used and suitable drugs for local delivery system. Additionally, some promising drugs including anti-inflammatory drugs, antioxidant drugs and drugs inhibiting cell proliferation and migration are already being tested in pre-clinical trials or animal models. At the same time, intraluminal and extraluminal delivery devices have also got a rapid development during the past decades. The efficacy of drug-eluting stent, drug-eluting balloon, porous and microporous balloon and the most recent drug-eluting bioresobable scaffold for preventing of restenosis in peripheral vessels have been demonstrated in humans or in animals, some of them even have received the CE mark in Europe. Endovascular microinfusion catheter and drug-loaded perivascular wraps have only been tested in animal models, more researches are needed. With the development of pharmacology and bioengineering, great strides will be made in the prevention of restenosis in the near future.
Mingyi
M
Zhang
Fuxian
F
Zhang
Huan
H
Zhang
Gangzhu
G
Liang
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D001158:Arteries; D023903:Coronary Restenosis / Q000517:prevention & control*; D016503:Drug Delivery Systems; D054855:Drug-Eluting Stents; D006801:Humans; D009204:Myocardial Revascularization; D017239:Paclitaxel; D020123:Sirolimus
D000893:Anti-Inflammatory Agents; D000903:Antibiotics, Antineoplastic; D017239:Paclitaxel; D020123:Sirolimus